This site uses cookies to simplify and improve your online experience.  You can find out more about cookies and how you can disable them by reading our Terms and Conditions. By continuing to browse this site you agree to our use of cookies on this device.

Roche Navigation Menu Roche Resources : Roche Resources
  • Sign in
  • Logout
  • Search
Roche
  • Up
  • Home
  • Search
  • Close search

						
							

Searching

    • Home
    • Roche Medicines
      Roche Medicines Overview
      • Oncology
      • Alecensa®▼(alectinib)
      • Kadcyla® (trastuzumab emtansine)
      • PERJETA® (pertuzumab)
      • PHESGO®▼ (pertuzumab/trastuzumab)
      • TECENTRIQ®▼ (atezolizumab)
      • Rozlytrek®▼(entrectinib)
      • Neuroscience
      • OCREVUS®▼ (ocrelizumab)
      • Haematology
      • POLIVY®▼ (polatuzumab vedotin)
      • Rare Diseases
      • Evrysdi®▼ (risdiplam)
      • HEMLIBRA®▼ (emicizumab)
    • Therapy Areas
      Therapy Areas Overview
      • Oncology
      • Breast Cancer
      • Haematology
      • Haematology
      • Neuroscience
      • Neuroscience
    • Congress and Meetings
      Congress and Meetings Overview
    • HCP Materials
      HCP Materials Overview
    • FAQs
      FAQs Overview
    • Prescribing Information
      Prescribing Information Overview
      • Find out more about:
      • ALECENSA®▼(alectinib) Great Britain
      • ALECENSA® (alectinib) Northern Ireland
      • Avastin® (bevacizumab) [Great Britain]
      • Avastin (bevacizumab) [Northern Ireland]
      • Evrysdi®▼(risdiplam)
      • GAZYVARO® (obinutuzumab) Great Britain
      • GAZYVARO® (obinutuzumab) Northern Ireland
      • HEMLIBRA®▼(emicizumab) Great Britain
      • HEMLIBRA®▼(emicizumab) Northern Ireland
      • Herceptin® (trastuzumab) IV
      • Herceptin® (trastuzumab) SC
      • Kadcyla® (trastuzumab emtansine)
      • OCREVUS®▼ (ocrelizumab) GB
      • OCREVUS®▼ (ocrelizumab) NI
      • Perjeta® (pertuzumab)
      • Phesgo®▼(pertuzumab/trastuzumab)
      • Polivy®▼(polatuzumab vedotin) Great Britain
      • Polivy®▼(polatuzumab vedotin) Northern Ireland
      • Rozlytrek® ▼(entrectinib)
      • TECENTRIQ®▼ (atezolizumab) Great Britain
      • Tecentriq® (atezolizumab) Northern Ireland
    • Adverse Event Reporting
      Adverse Event Reporting Overview
    • Home
    • Roche Medicines
      • Oncology
        • Alecensa®▼(alectinib)
        • Kadcyla® (trastuzumab emtansine)
        • PERJETA® (pertuzumab)
        • PHESGO®▼ (pertuzumab/trastuzumab)
        • TECENTRIQ®▼ (atezolizumab)
        • Rozlytrek®▼(entrectinib)
      • Neuroscience
        • OCREVUS®▼ (ocrelizumab)
      • Haematology
        • POLIVY®▼ (polatuzumab vedotin)
      • Rare Diseases
        • Evrysdi®▼ (risdiplam)
        • HEMLIBRA®▼ (emicizumab)
    • Therapy Areas
      • Oncology
        • Breast Cancer
      • Haematology
        • Haematology
      • Neuroscience
        • Neuroscience
    • Congress and Meetings
    • HCP Materials
    • FAQs
    • Prescribing Information
      • Find out more about:
        • ALECENSA®▼(alectinib) Great Britain
        • ALECENSA® (alectinib) Northern Ireland
        • Avastin® (bevacizumab) [Great Britain]
        • Avastin (bevacizumab) [Northern Ireland]
        • Evrysdi®▼(risdiplam)
        • GAZYVARO® (obinutuzumab) Great Britain
        • GAZYVARO® (obinutuzumab) Northern Ireland
        • HEMLIBRA®▼(emicizumab) Great Britain
        • HEMLIBRA®▼(emicizumab) Northern Ireland
        • Herceptin® (trastuzumab) IV
        • Herceptin® (trastuzumab) SC
        • Kadcyla® (trastuzumab emtansine)
        • OCREVUS®▼ (ocrelizumab) GB
        • OCREVUS®▼ (ocrelizumab) NI
        • Perjeta® (pertuzumab)
        • Phesgo®▼(pertuzumab/trastuzumab)
        • Polivy®▼(polatuzumab vedotin) Great Britain
        • Polivy®▼(polatuzumab vedotin) Northern Ireland
        • Rozlytrek® ▼(entrectinib)
        • TECENTRIQ®▼ (atezolizumab) Great Britain
        • Tecentriq® (atezolizumab) Northern Ireland
    • Adverse Event Reporting
    • Sign in
    • Logout
    Close

    1 - of results for ""

    No results

    This website is intended for healthcare professionals (HCPs) only. If you are an HCP, register free to access the full content.

    • Efficacy

      Read more

    • TECENTRIQ®▼ (atezolizumab)
    • HCC
      • Efficacy
      • QoL
      • Safety
      • MOA
      • Study design
    • NSCLC
      • Efficacy
      • Safety
      • How to Use
    • eNSCLC
    • More
      • HCC
      • NSCLC
      • eNSCLC

    You are here:

    1. Roche Medicines
    2. Oncology
    3. TECENTRIQ®▼ (atezolizumab)
    4. NSCLC
    5. Efficacy

    ▼Tecentriq is subject to additional monitoring in Great Britain. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. In Northern Ireland, a black triangle is not required for Tecentriq and it is not subject to additional monitoring.

    Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44(0)1707 367554.

    As Tecentriq is a biological medicine, healthcare professionals should report adverse reactions by brand name and batch number.

    Prescribing Information

    TECENTRIQ®▼(atezolizumab) Great Britain
    TECENTRIQ® (atezolizumab) Northern Ireland

    Adverse event reporting and additional monitoring

    TECENTRIQ provides an extra first-line treatment option for patients with metastatic NSCLC and high PD-L1 expression.2–4 Compared with platinum-based chemotherapy, it can give patients the chance of:

    Longer median OS

    •  Patients treated with TECENTRIQ had a median OS of 20.2 months (95% CI: 16.5–NE) vs 13.1 months (95% CI: 7.4–16.5) with chemotherapy (HR: 0.59; 95% CI: 0.40–0.89; p=0.01)1
    •  1-year OS was 64.9% (95% CI: 55.4–74.4) with TECENTRIQ vs 50.6% (95% CI: 40.0–61.3) with chemotherapy1

    > More

    Increased median PFS

    •  Median PFS was 8.1 months (95% CI: 6.8–11.0) with TECENTRIQ compared with 5.0 months (95% CI: 4.2–5.7) with chemotherapy (HR: 0.63; 95% CI: 0.45–0.88)1

    > More

    Higher ORR

    •  TECENTRIQ achieved an objective response in 38.3% of patients (95% CI: 29.1–48.2) vs 28.6% (95% CI: 19.9–38.6) with chemotherapy1

    > More

    Sustained HRQoL

    •  Patients’ overall HRQoL remained clinically stable through to week 57 of treatment with TECENTRIQ5
    •  Patients treated with chemotherapy experienced a clinically meaningful decline in overall HRQoL from week 42 onwards5

    > More

    Physicians should note that, before demonstrating a long-term survival benefit with atezolizumab, a higher proportion of patients on atezolizumab (16/107) died within 2.5 months of study randomisation, compared with 10/98 in the chemotherapy arm and as such, physicians should consider the delayed onset of atezolizumab effect before initiating first-line treatment as monotherapy in patients with NSCLC3,4


    • IMpower110 study design
      • IMpower110 was a randomised, open-label, multicentre, phase III trial which assessed the efficacy and safety of TECENTRIQ compared with platinum-based chemotherapy in patients with metastatic NSCLC whose disease was
        PD-L1 positive and was not EGFR-mutant or ALK-positive, and who had not previously received chemotherapy1,6

      Primary endpoint1

      • OS in patients without EGFR mutations or ALK translocations
      • OS was tested hierarchically:
        1. TC3 or IC3 population (PD-L1 expression on ≥50% of tumour cells or ≥10% of tumour-infiltrating immune cells)
        2. TC2/3 or IC2/3 population (PD-L1 expression on ≥5% of tumour cells or tumour-infiltrating immune cells)
        3. TC1/2/3 or IC1/2/3 population (PD-L1 expression on ≥1% of tumour cells or tumour-infiltrating immune cells)

      Key secondary endpoints1

      • Investigator-assessed PFS according to RECIST, v1.1
      • ORR
      • DoR
      • OS and investigator-assessed PFS according to RECIST, version 1.1 in prespecified subgroups with respect to PD-L1 expression (defined by the SP263 immunohistochemical assay) and blood-based tumour mutational burden
      • Safety (assessed in all treated patients regardless of PD-L1 expression, EGFR or ALK status)

    Learn more about the practicalities of administering TECENTRIQ


    • Baseline characteristics
      • Baseline characteristics were generally balanced between treatment groups1

      *The TC1/2/3 or IC1/2/3 population was defined as patients with PD-L1 expression on ≥1% of tumour cells or tumour-infiltrating immune cells. The TC3 or IC3 population was defined as patients with PD-L1 expression on ≥50% of tumour cells or ≥10% of tumour-infiltrating immune cells. Both population are comprised of patients who did not have EGFR-mutant or ALK-positive disease.
      †Race was reported by the patients. One patient in the TECENTRIQ TC1/2/3 or IC1/2/3 population was categorised as having multiple races (not shown).
      Adapted from Herbst1


    TECENTRIQ offers your patients significantly longer median OS vs platinum-based chemotherapy1

    Median OS - primary endpoint. TC or IC 3 population1

    15.7 months’ median follow-up (range 0–35 months).
    Adapted from Herbst1

    Physicians should note that, before demonstrating a long-term survival benefit with atezolizumab, a higher proportion of patients on atezolizumab (16/107) died within 2.5 months of study randomisation, compared with 10/98 in the chemotherapy arm and as such, physicians should consider the delayed onset of atezolizumab effect before initiating first-line treatment as monotherapy in patients with NSCLC3,4

    In the TC/IC3 population, 64.9% of patients treated with TECENTRIQ lived for at least 1-year7

    Landmark OS1,7

    15.7 months’ median follow-up (range 0–35 months).
    Adapted from Herbst1 and Data on File M-GB-000033647

    • The 18-month OS rate was 54.6% (95% CI: 43.4–65.7) with TECENTRIQ vs 27.3% (95% CI: 15.5–39.1) with chemotherapy5
    • In the IMpower110 trial, treatment with TECENTRIQ could continue after disease progression in patients who had a continued clinical benefit1

     

    See how the safety profile of TECENTRIQ compared with that of chemotherapy


    • For the TC/IC3 population, PFS was 8.1 months with TECENTRIQ compared with 5.0 months with platinum-based chemotherapy¹

      Median PFS – secondary endpoint1

      15.7 months’ median follow-up (range 0–35 months).
      Adapted from Herbst1

      In the TC/IC3 population, 36.9% of patients treated with TECENTRIQ lived for at least 1 year without disease progression1

      Landmark PFS1

      15.7 months’ median follow-up (range 0–35 months).
      Adapted from Herbst1


    • ORR and DoR – secondary endpoints¹

      In the TC/IC3 population, TECENTRIQ achieved an objective response in 38.3% of patients vs 28.6% with platinum-based chemotherapy1

      15.7 months’ median follow-up (range 0–35 months).
      Adapted from Herbst1

      • At data cut-off, responses were ongoing in 68.3% of patients treated with TECENTRIQ vs 35.7% of patients with chemotherapy1

    |


    • Patients’ overall HRQoL was sustained through to week 57 with TECENTRIQ and declined from week 42 with platinum-based chemotherapy⁵
      • Patients’ overall HRQoL remained clinically stable through to week 57 of treatment with TECENTRIQ5
      • Patients treated with chemotherapy experienced a clinically meaningful decline in overall HRQoL from week 42 onwards5

      Mean change from baseline on the QLQ-C30 Global Health Status Scale – exploratory endpoint5

      Adapted from De Marinis5

       


      TECENTRIQ is a cost-effective treatment option for the NHS
      2

       

    |


    ALK, anaplastic lymphoma kinase; AUC, area under the curve; CI, confidence interval; DoR, duration of response; ECOG, European Cooperative Oncology Group; EGFR, epidermal growth factor receptor; HR, hazard ratio; HRQoL, health-related quality of life; NE, not estimable; NSCLC, non-small cell lung cancer; ORR, objective response rate; OS, overall survival; PD-L1, programmed death ligand 1; PFS, progression-free survival; PS, performance status; q3w, every 3 weeks; RECIST, Response Evaluation Criteria in Solid Tumours.

    References:

    1. Herbst RS et al. N Engl J Med 2020; 383(14): 1328–1339.
    2. NICE. Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer (TA705). June 2021.
    3. TECENTRIQ GB Summary of Product Characteristics.
    4. TECENTRIQ NI Summary of Product Characteristics.
    5. De Marinis F et al. Presented at the ASCO Annual Meeting; May 29–31, 2020. Poster #360.
    6. Spigel DR et al. Presented at the ESMO Congress, Barcelona, Spain; 27 September to 1 October, 2019. Oral presentation.
    7. Roche. Data on File M-GB-00003364. April 2021.


    M-GB-00006874
    Date of preparation: April 2022

    Welcome to Roche Resources

    Roche Resources is intended for UK Healthcare Professionals only. By entering this site you are confirming that you are a UK Healthcare professional.

    I am a healthcare professional I am a member of the public
    • © 2022 Roche Products Limited
    • 01.07.2022
    • Terms and Conditions
    • Privacy Policy
    • Prescribing Information
    • Contact

    This is a promotional website intended for UK healthcare professionals, designed, built and funded by Roche Products Ltd. This website is intended to be viewed on a desktop/laptop. M-GB-00008047 Date of Preparation June 2022.